Delcath Systems, Inc. (NASDAQ:DCTH) was up by 7.14% closed to $1.80. The stock is moving marginally above its 50 days moving average of $1.61. The stock has 75.08 million shares outstanding, with a market capitalization of $135.14 million; 3.19 million shares exchanged hands in the last trading session. The chart looks strong for the stock and has been in the upward trend since past four months. The 52-week range of the stock is $1.01 – $3.31. Focusing on the field of oncology DCTCH specializes in pharmaceutical and medical device. The median target price of the stock is $3.50, which is double the current price of the stock. Revenue is estimated to be $4mm for the current fiscal year from its previous revenue if $400k in FY2012. The company is expected to receive an FDA announcement in mid-June.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) was up by 6.40% and closed to $1.83. The stock is trading above its 50 days moving average of $4.41 and has a RSI of 22 and has experienced huge volume thus the stock is oversold. ZIOP’s cancer drug Palifosfamide performed badly in its 447 patient phase 3 trial in metastatic soft tissue sarcoma. ZIOP’s Chief Executive Jonathan Lewis stated that as per (the) progression-free survival (RATE), ZIOP does’nt expect to get the drug approved anywhere across the globe. ZIOP announced that it will discontinue the development of the drug. ZIOP’S drug Ad-RTS IL-12 currently in the Phase 2 trial to cure advanced melanoma and together with Palifosfamide will cure metastatic breast cancer. Another drug Indibulin which is currently in Phase I and 2 clinical trial will cure metastatic breast cancer. ZIOP’s drug Darinaparsin for the treatment of Advanced Solid Tumors has completed its Phase 1 testing. For the stock to outperform the drug Ad-RTS IL-12 need to succeed in its Phase 2 trial. The current cash equivalent of the company is $73.3 million, which will exhaust by the first half of 2013, and for further clinical trials of the product in pipeline, the company will need large amount of cash. After the failure of Palifosfamide ZIOP is going to face trouble in raising cash, thus the only option left with the company to meet its cash is public offer. ZIOP reported a net loss of $102.1 million for FY2012, and with its drug in its beginning state and other drug in its mid-stage, the market capitalization of $149.33 million is not justified.
Velti Plc (NASDAQ:VELT) the stock was up by 5.85% and closed to $1.99, is trading way below its 50 day moving average of $3.61. It has a RSI of 27.58 which indicate that the stock is in the oversold zone, trading marginally above its 52-week low of $1.85 made on March 19. The stock has declined since past six months. The 52-week range for the stock is $1.87 – $2.04, with 65 million shares outstanding. 2.83 million shares exchanged hands in the last trading session. The market capitalization of the stock is $129.34 million, with a beta of 0.37.